PA
ITCI

Parallel Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Parallel Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,982
Closed -$261K – 3737
2025
Q1 		$261K Buy
1,982
+27
+1% +$3.37K 0.01% 840
2024
Q4 		$163K Buy
1,955
+64
+3% +$5.26K ﹤0.01% 1023
2024
Q3 		$138K Buy
1,891
+277
+17% +$20.8K ﹤0.01% 1106
2024
Q2 		$111K Buy
1,614
+15
+0.9% +$1.04K ﹤0.01% 1136
2024
Q1 		$111K Buy
1,599
+35
+2% +$2.41K ﹤0.01% 1121
2023
Q4 		$112K Buy
1,564
+219
+16% +$12.6K ﹤0.01% 1069
2023
Q3 		$70.1K Buy
1,345
+113
+9% +$6.58K ﹤0.01% 1237
2023
Q2 		$78K Hold
1,232
– – ﹤0.01% 1188
2023
Q1 		$66.7K Sell
1,232
-1,272
-51% -$61.5K ﹤0.01% 1232
2022
Q4 		$133K Sell
2,504
-3
-0.1% -$150 0.01% 876
2022
Q3 		$117K Buy
2,507
+3
+0.1% +$157 0.01% 898
2022
Q2 		$143K Sell
2,504
-22
-0.9% -$1.25K 0.01% 826
2022
Q1 		$152K Sell
2,526
-118
-4% -$6.13K 0.01% 834
2021
Q4 		$138K Sell
2,644
-6
-0.2% -$252 0.01% 890
2021
Q3 		$99K Buy
2,650
+150
+6% +$5.21K ﹤0.01% 988
2021
Q2 		$102K Hold
2,500
– – ﹤0.01% 949
2021
Q1 		$85K Hold
2,500
– – ﹤0.01% 955
2020
Q4 		$80K Hold
2,500
– – ﹤0.01% 898
2020
Q3 		$64K Buy
+2,500
New +$57K ﹤0.01% 970

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Parallel Advisors's ITCI Position: Q2 2025 in Review

Parallel Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,982 shares — an estimated $261K sold.

Parallel Advisors first reported a position in ITCI in Q3 2020 and held it in 19 quarters. The position peaked at $261K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Parallel Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Parallel Advisors sold 1,982 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $261K.
  • Parallel Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 19 quarters.
  • Parallel Advisors's Intra-Cellular Therapies Inc. position peaked at $261K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.